Xiao-Jun Xu1, Hong-Sheng Wang2, Xiu-Li Ju3, Pei-Fang Xiao4, Yan Xiao5, Hong-Man Xue6, Hong-Yu Shi7, Yi-Jin Gao8, Guo-Cun Jia9, Xue-Rong Li10, Wei-Hong Zhao11, Ning-Ling Wang12, Yong-Min Tang1. 1. Department of Hematology/Oncology, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, P.R. China. 2. Department of Hematology/Oncology, Children's Hospital of Fudan University, Shanghai, P.R. China. 3. Department of Pediatrics, Qilu Hospital of Shandong University, Ji'nan, P.R. China. 4. Department of Hematology/Oncology, Children's Hospital of Soochow University, Soochow, P.R. China. 5. Department of Pediatrics, Wuhan Union Hospital, Wuhan, P.R. China. 6. Department of Pediatrics, Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou, P.R. China. 7. Department of Hematology, Children's Hospital of Shanxi, Taiyuan, P.R. China. 8. Department of Hematology/Oncology, Shanghai Children's Medical Center, Shanghai, P.R. China. 9. Department of Pediatrics, Children's Hospital of Zhengzhou, Zhengzhou, P.R. China. 10. Department of Pediatrics, the Affiliated Hospital of Qingdao University, Qingdao, P.R. China. 11. Department of Pediatrics, Peking University First Hospital, Beijing, P.R. China. 12. Department of Pediatrics, Second Affiliated Hospital of Anhui Medical University, Hefei, P.R. China.
Abstract
BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a heterogeneous disease with major diagnostic and therapeutic difficulties. A large-scale multicenter study of pediatric HLH is still lacking in China. PROCEDURE: The Histiocytosis Study Group of the Chinese Pediatric Society conducted this retrospective study in 2014. A total of 323 patients diagnosed with HLH between 2011 and 2013 from 12 hospitals were registered. RESULTS: The median age at diagnosis was 2.2 years (range, 0-14.6 years), with a peak age of HLH onset at 0 to 3 years (63%). Mutations in HLH-related genes were found in 27.9% (24/86) patients who underwent genetic testing. PRF1, UNC13D, STXBP2 and LYST were the predominant genes involved. Sixteen patients (66.7%) presented with only monoallelic mutations in one gene. Epstein-Barr virus (EBV) infection was the major condition related to HLH, which was documented in 74.4% (201/270) of the patients who underwent EBV detection. Of 252 evaluable patients, 64.7% (163) achieved non-active disease at the eighth week and patients treated with a protocol containing etoposide presented higher remission rates (75.6% vs. 46.8%, P < 0.001). In multivariate analysis, a younger age at diagnosis (<12 months), platelet count less than 80×109 /L, central nervous system involvement, and initial treatment using a protocol without etoposide (not HLH-94/04) were independent prognostic factors indicating resistant disease. DISCUSSION: This study first multicenter assessment of HLH in China shows some different features in Chinese children with HLH compared with those in western countries, including older age, vulnerability to EBV infection, and a high proportion of patients with single monoallelic genetic mutations.
BACKGROUND:Hemophagocytic lymphohistiocytosis (HLH) is a heterogeneous disease with major diagnostic and therapeutic difficulties. A large-scale multicenter study of pediatric HLH is still lacking in China. PROCEDURE: The Histiocytosis Study Group of the Chinese Pediatric Society conducted this retrospective study in 2014. A total of 323 patients diagnosed with HLH between 2011 and 2013 from 12 hospitals were registered. RESULTS: The median age at diagnosis was 2.2 years (range, 0-14.6 years), with a peak age of HLH onset at 0 to 3 years (63%). Mutations in HLH-related genes were found in 27.9% (24/86) patients who underwent genetic testing. PRF1, UNC13D, STXBP2 and LYST were the predominant genes involved. Sixteen patients (66.7%) presented with only monoallelic mutations in one gene. Epstein-Barr virus (EBV) infection was the major condition related to HLH, which was documented in 74.4% (201/270) of the patients who underwent EBV detection. Of 252 evaluable patients, 64.7% (163) achieved non-active disease at the eighth week and patients treated with a protocol containing etoposide presented higher remission rates (75.6% vs. 46.8%, P < 0.001). In multivariate analysis, a younger age at diagnosis (<12 months), platelet count less than 80×109 /L, central nervous system involvement, and initial treatment using a protocol without etoposide (not HLH-94/04) were independent prognostic factors indicating resistant disease. DISCUSSION: This study first multicenter assessment of HLH in China shows some different features in Chinese children with HLH compared with those in western countries, including older age, vulnerability to EBV infection, and a high proportion of patients with single monoallelic genetic mutations.
Authors: P Malik; L Antonini; P Mannam; F N Aboobacker; A Merve; K Gilmour; K Rao; S Kumar; S E Mani; D Eleftheriou; A Rao; C Hemingway; S V Sudhakar; J Bartram; K Mankad Journal: AJNR Am J Neuroradiol Date: 2021-10-07 Impact factor: 3.825
Authors: Laura Viñas-Giménez; Natàlia Padilla; Laura Batlle-Masó; Ferran Casals; Jacques G Rivière; Mónica Martínez-Gallo; Xavier de la Cruz; Roger Colobran Journal: Front Immunol Date: 2020-01-31 Impact factor: 7.561
Authors: Michael B Jordan; Carl E Allen; Jay Greenberg; Michael Henry; Michelle L Hermiston; Ashish Kumar; Melissa Hines; Olive Eckstein; Stephan Ladisch; Kim E Nichols; Carlos Rodriguez-Galindo; Birte Wistinghausen; Kenneth L McClain Journal: Pediatr Blood Cancer Date: 2019-07-24 Impact factor: 3.167
Authors: Marjan Huizing; May C V Malicdan; Jennifer A Wang; Hadass Pri-Chen; Richard A Hess; Roxanne Fischer; Kevin J O'Brien; Melissa A Merideth; William A Gahl; Bernadette R Gochuico Journal: Hum Mutat Date: 2020-01-23 Impact factor: 4.700
Authors: Rawan Amir; Asim Kichloo; Jagmeet Singh; Ravinder Bhanot; Michael Aljadah; Akshay Kumar; Michael Stanley Albosta; Shantanu Solanki Journal: J Investig Med High Impact Case Rep Date: 2020 Jan-Dec